{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:43:35Z","timestamp":1784958215664,"version":"3.55.0"},"reference-count":23,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":437,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chemotherapeutic agents result in the loss of growing follicles, which can manifest as amenorrhoea. Alkylating chemotherapy (AC) is known to be more gonadotoxic than non-alkylating chemotherapy (NAC). Anti-M\u00fcllerian hormone (AMH), an indirect marker of ovarian reserve, and age have been investigated as predictors of ovarian function after chemotherapy; however, little is known about the time to return of menses. This study aimed to assess how patient age and baseline serum AMH levels at cancer diagnosis affect the time to return of menses post-chemotherapy. This retrospective cohort study examined oncology patients (n = 67) who underwent chemotherapy and were treated through the Reproductive Services Unit of two institutions in Melbourne, Australia. Primary outcomes included the correlation between age and baseline AMH with time to return of menses after chemotherapy. Secondary outcomes include the change in AMH levels at 6- and 12-months post-completion of chemotherapy. Pairwise correlation of the pre-chemotherapy AMH level and time to return of menses demonstrated statistical significance (Spearman\u2019s coefficient, \u03c1 = \u22120.40) for patients who underwent AC. This analysis in breast cancer patients who underwent AC displayed a negative correlation but was not statistically significant. No association was found between age and time to return of menses for all cancer (NAC or AC) or breast cancer patients who underwent AC. Higher AMH levels prior to AC were associated with an earlier return of menses after chemotherapy. Age at the commencement of chemotherapy was not associated with return of menses. Further prospective research is required to assess post-chemotherapy recovery of AMH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>Chemotherapy, used to treat cancer, is known to damage women\u2019s ovaries, with certain types having a more toxic effect than others. This may result in a temporary loss of periods while undergoing chemotherapy. AMH is a hormone produced by the ovaries and gives an indication of their level of function. This study looks at whether an individual's AMH or age when beginning chemotherapy can predict the time before the resumption of periods after completing chemotherapy. This study found that for cancer patients who underwent the chemotherapy type known to be more toxic to ovaries, the higher their AMH level was before beginning chemotherapy, the more rapidly their periods would return after completing chemotherapy. Age was not found to accurately predict how rapidly periods would return after completing chemotherapy. This information can be used to inform patients before treatment of the chances of periods returning and, consequentially, pregnancy after the completion of their chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/raf-24-0046","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:59:21Z","timestamp":1734530361000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-13","source":"Crossref","is-referenced-by-count":4,"title":["Age and serum anti-M\u00fcllerian hormone levels as predictors of time to return of menses after chemotherapy"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-8249","authenticated-orcid":true,"given":"Madhavi-Priya","family":"Singh","sequence":"first","affiliation":[{"name":"Austin Health 1 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-2247","authenticated-orcid":true,"given":"Rashi","family":"Kalra","sequence":"additional","affiliation":[{"name":"Melbourne IVF 2 , , ,","place":["East Melbourne, Victoria, Australia"]},{"name":"Royal Women\u2019s Hospital 3 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Agresta","sequence":"additional","affiliation":[{"name":"Melbourne IVF 2 , , ,","place":["East Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-1612","authenticated-orcid":true,"given":"Alec","family":"Leos","sequence":"additional","affiliation":[{"name":"The University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-1037","authenticated-orcid":true,"given":"Samith Minu","family":"Alwis","sequence":"additional","affiliation":[{"name":"Austin Health 1 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4535-1854","authenticated-orcid":true,"given":"Alex","family":"Polyakov","sequence":"additional","affiliation":[{"name":"Royal Women\u2019s Hospital 3 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"The University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Genea 5 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-1645","authenticated-orcid":true,"given":"Genia","family":"Rozen","sequence":"additional","affiliation":[{"name":"Royal Women\u2019s Hospital 3 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"Genea 5 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-1632","authenticated-orcid":true,"given":"Kate","family":"Stern","sequence":"additional","affiliation":[{"name":"Melbourne IVF 2 , , ,","place":["East Melbourne, Victoria, Australia"]},{"name":"Royal Women\u2019s Hospital 3 , , ,","place":["Melbourne, Victoria, Australia"]},{"name":"The University of Melbourne 4 , , ,","place":["Melbourne, Victoria, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2026070713213520500_bib1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2010-2582","article-title":"Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer","volume":"96","author":"Anderson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713213520500_bib2","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.ejca.2013.07.014","article-title":"Pretreatment anti-m\u00fcllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer","volume":"49","author":"Anderson","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026070713213520500_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2017.10.001","article-title":"The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer","volume":"87","author":"Anderson","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026070713213520500_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/humupd\/dmac004","article-title":"Anti-m\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review","volume":"28","author":"Anderson","year":"2022","journal-title":"Hum Reprod Update"},{"key":"2026070713213520500_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after hodgkin lymphoma treatment within the German hodgkin study group hd13 to hd15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070713213520500_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1210\/jc.2011-3180","article-title":"Anti-m\u00fcllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study","volume":"97","author":"Brougham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713213520500_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12916-016-0699-y","article-title":"Back to the basics of ovarian aging: a population-based study on longitudinal anti-Mullerian hormone decline","volume":"14","author":"de Kat","year":"2016","journal-title":"BMC Med"},{"key":"2026070713213520500_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.rbmo.2009.11.010","article-title":"Anti-m\u00fcllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results","volume":"20","author":"Decanter","year":"2010","journal-title":"Reprod BioMedicine Online"},{"key":"2026070713213520500_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.rbmo.2018.02.004","article-title":"Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy","volume":"36","author":"Decanter","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2026070713213520500_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.fertnstert.2012.09.039","article-title":"Pretreatment antim\u00fcllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy","volume":"99","author":"Dillon","year":"2013","journal-title":"Fertil Steril"},{"key":"2026070713213520500_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/rep.0.1240601","article-title":"Regulation of ovarian function: the role of anti-Mullerian hormone","volume":"124","author":"Durlinger","year":"2002","journal-title":"Reproduction"},{"key":"2026070713213520500_bib12","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/annonc\/mdx349","article-title":"Chemotherapy-induced toxicity\u2014a secondary effect caused by released DNA?","volume":"28","author":"Helleday","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070713213520500_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/1933719115618284","article-title":"Usefulness of the ultrasensitive anti-Mullerian hormone assay for predicting true ovarian reserve","volume":"23","author":"Iwase","year":"2016","journal-title":"Reprod Sci"},{"key":"2026070713213520500_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.fertnstert.2015.11.020","article-title":"Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all","volume":"105","author":"Jacobson","year":"2016","journal-title":"Fertil Steril"},{"key":"2026070713213520500_bib15","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.3390\/ijms22147484","article-title":"Molecular mechanism and prevention strategy of chemotherapy- and radiotherapy-induced ovarian damage","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026070713213520500_bib16","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.26403","article-title":"Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer","volume":"118","author":"Letourneau","year":"2012","journal-title":"Cancer"},{"key":"2026070713213520500_bib17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejogrb.2020.09.016","article-title":"Evolution of serum anti-M\u00fcllerian hormone (amh) level in young women treated with chemotherapy for breast cancer according to basal amh level","volume":"254","author":"Loubersac","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026070713213520500_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-12-26","article-title":"Serum amh level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review","volume":"12","author":"Peign\u00e9","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"2026070713213520500_bib19","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.4161\/cc.26358","article-title":"Ovarian follicle burnout: a universal phenomenon?","volume":"12","author":"Roness","year":"2013","journal-title":"Cell Cycle"},{"key":"2026070713213520500_bib20","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.28942","article-title":"Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients","volume":"120","author":"Su","year":"2014","journal-title":"Cancer"},{"key":"2026070713213520500_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MED.0000000000000447","article-title":"The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery","volume":"25","author":"Wong","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070713213520500_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10549-018-4997-2","article-title":"Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer","volume":"173","author":"Xue","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026070713213520500_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bpobgyn.2009.08.008","article-title":"Reproduction after breast cancer","volume":"24","author":"Zervoudis","year":"2010","journal-title":"Best Pract Res Clin Obstet Gynaecol"}],"container-title":["Reproduction and Fertility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/raf.bioscientifica.com\/view\/journals\/raf\/6\/1\/RAF-24-0046.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/raf.bioscientifica.com\/downloadpdf\/journals\/raf\/6\/1\/RAF-24-0046.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-24-0046\/147306\/raf-24-0046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-24-0046\/147306\/raf-24-0046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:50:20Z","timestamp":1783446620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article\/6\/1\/e240046\/26275\/Age-and-serum-anti-Mullerian-hormone-levels-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/raf-24-0046","relation":{},"ISSN":["2633-8386"],"issn-type":[{"value":"2633-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"e240046"}}